EP1933844A1 - Kombination - Google Patents
KombinationInfo
- Publication number
- EP1933844A1 EP1933844A1 EP06792208A EP06792208A EP1933844A1 EP 1933844 A1 EP1933844 A1 EP 1933844A1 EP 06792208 A EP06792208 A EP 06792208A EP 06792208 A EP06792208 A EP 06792208A EP 1933844 A1 EP1933844 A1 EP 1933844A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- component
- components
- use according
- medicament
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a combination comprising at least one nonsteroidal antiinflammatory drugs (NSAIDs) and at least one proton pump inhibitor for the prevention and / or treatment of tumor diseases, drugs containing them and their preparation.
- NSAIDs nonsteroidal antiinflammatory drugs
- proton pump inhibitor for the prevention and / or treatment of tumor diseases, drugs containing them and their preparation.
- FAP familial adenomatous polyposis
- adenomatous polyps are estimated at about 33% 50% of the total population around the age of 50 and around 50% at the age of 70 (Williams AR, BaIasororiva BA, Day DW, Polyps and Cancer of the Long Bowel: a necropsy study in Liverpool, Gut. 23, 835-842). Histologically, neoplasms are adenomas.
- NSAIDs non-steroidal anti-inflammatory drugs
- O-acetylsalicylic acid has been shown to be prophylactic in the development of colon cancer, breast cancer, and in experimental models of lung cancer (Harris RE, Kasbari S, Farrar WB, Prospective study of nonsteroidal anti-inflammatory and breast cancer., Oncology Reports 1998, 6, 71-73 Rioux N., Castonguay A. Prevention of NNK-induced lung tumorigenesis in AJJ mice by acetylsalicylic acid and NS 398. Cancer research 1998, 58, 5354 to 5360).
- high doses or long-term use of NSAIDs may cause undesirable side effects in, for example, the gastrointestinal area (Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs, N Engl J Med 1999; 340: 1888-1899 (Erratum, N Engl J med 1999; 341: 548).
- the object of the present invention is to provide a combination for the prevention and / or treatment of tumor diseases comprising an NSAID, wherein NSAID-related undesired side effects are reduced.
- the present invention relates to a combination comprising at least one NSAID as component A and at least one proton pump inhibitor as component B for the prevention and / or treatment of tumor diseases.
- NSAID non-steroidal antiinflammatory drugs
- NSAIDs are, for example, aceclofenac, acetaminophen, o-acetylsalicylic acid, alclofenac, alminprofen, amfenac, ampiroxicam, amtolmetinguacil, anirolac, antrafenin, azapropazone, benorilate, bermoprofen, bindarit, bromfenac, bucloxin acid, bucolome, bufexamac, bumadizone, butibufen, Butixrate, Carbasalate Calcium, Carprofen, Cinmetacin, Cinnoxicam, Clidanac, Clobuzarite, Deboxamet, Dexibuprofen, Dexketoprofen, Diclofenac, Diflunisal, Eltenac, Enfenamic Acid, Eat Salate, Et
- NSAIDs are acetaminophen, o-acetylsalicylic acid, clidanac, diclofenac, flurbiprofen, ibuprofen, ketoprofen and sulindac. Particularly preferred as the NSAID is o-acetylsalicylic acid.
- proton pump inhibitor generally stands for all substance classes listed under this term in the prior art.
- Proton pump inhibitor is, for example, ranitidine, famotidine, pantoprazole, lansoprazole, esomeprazole, omeprazole and rabeprazole.
- Pantoprazole, rabeprazole, lansoprazole, esomeprazole and omeprazole are preferred as proton pump inhibitors.
- Particularly preferred proton pump inhibitors are lansoprazole, esomeprazole and omeprazole.
- the compounds present in the combination according to the invention can also be used in the form of their salts, solvates and solvates of the salts, as long as they are not already salts, solvates and solvates of the salts.
- the compounds present in the combination according to the invention can also exist in stereoisomeric forms (enantiomers, diastereomers), depending on their structure.
- the invention therefore includes the enantiomers or diastereomers and their respective mixtures.
- the present invention encompasses all tautomeric forms.
- Salts used in the context of the present invention are physiologically acceptable salts of the compounds according to the invention. However, also included are salts which are not suitable for pharmaceutical applications themselves but can be used, for example, for the isolation or purification of the compounds according to the invention.
- Physiologically acceptable salts of the compounds according to the invention include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, for example hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, ethanesulfonic, toluenesulfonic, benzenesulfonic, naphthalenedisulfonic, acetic, trifluoracetic, propionic, lactic Malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.
- Physiologically acceptable salts of the compounds according to the invention also include salts of customary bases, such as, by way of example and by way of preference, alkali metal salts (for example sodium and potassium salts), alkaline earth salts (for example calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having from 1 to 16 carbon atoms, as exemplified and preferably ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methyl-mo ⁇ holin, arginine, lysine, ethylenediamine and N-methylpiperidine.
- alkali metal salts for example sodium and potassium salts
- alkaline earth salts for example calcium and magnesium salts
- ammonium salts derived from ammonia or organic amine
- Solvates in the context of the invention are those forms of the compounds according to the invention which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates that coordinate with water.
- the erfindunbe combination can be used for the prevention and / or treatment of tumor diseases.
- tumor diseases are cancerous diseases of the organs of warm-blooded organisms and their precursors, in particular tumor diseases, in which therapeutic effects can be achieved by inhibiting Cox-1 and / or Cox-2.
- tumor diseases are carcinomas of the gastrointestinal tract and its appendages such as the liver, pancreas, especially the small intestine, the colon, the rectum and their precursors.
- Precursors are changes that are not yet cancerous, preferably colon polyps, for example, adenomatous intestinal polyps.
- tumor diseases in the context of the invention are lung cancers, tumors of the skin, in particular melanomas, prostate cancers, breast cancers, skeletal tumors, lymphatic tumors, tumors of the ovaries, tumors of the endocrine system and tumors of the central nervous system.
- the combination according to the invention can be used for the prevention and / or treatment of lung carcinomas, breast cancers, tumors of the ovaries and carcinomas of the gastrointestinal tract such as the small intestine, the colon and the rectum.
- the combination according to the invention can be used for the prevention and / or treatment of familial adenomatous polyposis (FAP), familial non-polyposis tumor disease (HNPCC), as well as primary or secondary chemoprevention and therapy of colorectal carcinoma ,
- FAP familial adenomatous polyposis
- HNPCC familial non-polyposis tumor disease
- Primary prevention means the protection of patients from a first disease that causes organ damage.
- Secondary prevention in this context means the protection of patients who have already suffered organ damage as a result of a tumor disease from a new tumor disease.
- the synergistic effect of the combination according to the invention is preferably observed when the combination according to the invention contains 0.1 to 20 mg / kg, in particular 0.5 to 15 mg / kg of active ingredient of component A and 0.01 to 15 mg / kg, in particular 0.05 to 10 mg / kg of active ingredient of component B in each case based on kg body weight of the patient when administered orally.
- the synergistic effect of the combination according to the invention is preferably observed when the combination according to the invention as NSAID o-acetylsalicylic acid in a dosage of 25 to 1500 mg, preferably in a dosage of 75 to 750 mg, and as proton pump inhibitor omeprazole in a dosage of 5 to 100 mg, preferably in a dosage of 15 to 50 mg, more preferably in a dosage of 20 to 40 mg, pantoprazole in a dosage of 5 to 100 mg, preferably in a dosage of 15 to 50 mg, more preferably in a dosage of 20 to 40 mg, lansoprazole 5 to 100 mg, preferably in a dosage of 10 to 50 mg, more preferably in a dosage of 15 to 30 mg, or esomeprazole in a dosage of 5 to 100 mg, preferably in one Dosage of 15 to 50 mg, more preferably in a dosage of 20 to 40 mg.
- a combination comprising as component A o-acetylsalicylic acid and as component B pantoprazole, lansoprazole, esomeprazole or omeprazole.
- Particularly preferred is a combination comprising as component A o-acetylsalicylic acid and as component B lansoprazole or omeprazole.
- the synergistic effect of the combinations according to the invention is preferably observed when the components A and B of the combination according to the invention are present in a ratio of 2: 1 to 100: 1, preferably 2: 1 to 40: 1, based on A and B.
- Ratio in the sense of the invention is understood to mean the weight ratio of the individual components, unless stated otherwise.
- the combination according to the invention is furthermore distinguished by a surprisingly good compatibility.
- the combination of the invention is preferably used in human medicine, but is also suitable for veterinary medicine, in particular for the treatment of mammals.
- the administration of the combinations according to the invention may be parenteral, topical or oral, preferably topical or oral, more preferably oral.
- Another object of the present invention is the use of the erf ⁇ ndungswen combination for the preparation of dosage forms for the prevention and / or treatment of tumor diseases.
- Combinations within the meaning of the invention not only pharmaceutical forms containing all components (so-called. Fixed combinations), and combination packs containing the components separately, understood, but also simultaneously or temporally staggered applied components, if they are for treatment or prophylaxis
- the individual components can then be administered in different dosage forms. present (eg in different tablets and / or capsules), which are then used simultaneously or at different times for the treatment or prophylaxis of the same disease.
- the active compounds of components A and B can be converted in a known manner in the form of medicaments or dosage forms into the customary formulations, which may be liquid or solid formulations. Examples are tablets, dragees, pills, capsules, granules, aerosols, syrups, emulsions, suspensions, juices, ointments, creams, powders and solutions.
- impregnated patches or dressings can be used with the combination according to the invention. Rules for the preparation of these administration forms containing the combination according to the invention are known to the person skilled in the art.
- the erf ⁇ ndungsdorfen combinations are well tolerated and partially effective even at low dosages, the most diverse formulation variants can be realized.
- the individual components A and B need not necessarily be taken at the same time, but a staggered intake to achieve optimal effects may be advantageous.
- the components are each in separate containers, e.g. may be tubes, vials or blister packs.
- Such separate packaging of the components in a common primary packaging is also referred to as a kit.
- fixed combination should be understood here to mean those dosage forms in which the components are present together in a defined quantitative ratio
- Such fixed combinations can be realized in the liquid or solid formulations already mentioned, for example as solutions, capsules or tablets.
- the combinations according to the invention are dosed up to 3 times a day, preferred are those combinations which allow a 1 to 2 times daily application.
- the active ingredients of components A and B are particularly suitable to be formulated in a fixed combination in the form of a solid peroral dosage form. It is well known that patient compliance depends critically on the number of dosage forms per administration and the size and weight of the (solid peroral) dosage form. Therefore, both the number of different medicines to be taken separately should be as low as possible (the advantage of a fixed combination on), as well as the size and weight of a solid peroral dosage form to be as small as possible with full therapeutic potency, to make the intake as comfortable as possible for the patient. This allows fixed combinations in the form of solid peroral pharmaceutical formulations with minimal size and minimum weight realized. Accordingly, the fixed combinations according to the invention offer the highest possible patient compliance and thereby decisively improve the safety and reliability of a therapy.
- the drug release can be controlled.
- the above-mentioned temporal decoupling of the onset of action can also be realized in fixed combinations.
- the solid peroral dosage forms listed here are prepared according to the general standard procedures.
- Ingredients are those which are pharmaceutically accepted and physiologically harmless, for example: as fillers cellulose derivatives (eg microcrystalline cellulose), sugars (eg lactose), sugar alcohols (eg mannitol, sorbitol), inorganic fillers (eg calcium phosphates), binders (eg polyvinylpyrrolidone , Gelatin, starch and cellulose derivatives), as well as all other auxiliaries which are needed for the preparation of pharmaceutical formulations of the desired properties, eg Lubricant (magnesium stearate), e.g.
- Lubricant magnesium stearate
- Disintegrants e.g., cross-linked polyvinylpyrrolidone, sodium carboxymethylcellulose
- Wetting agents e.g., sodium lauryl sulfate
- Retarding agents e.g., cellulose derivatives, polyacrylic acid derivatives
- Stabilizers e.g. Flavors, eg. Color pigments.
- Liquid formulations are also prepared by standard method with pharmaceutically acceptable excipients and contain the active ingredients either dissolved or suspended. Typical application volumes of these pharmaceutical preparations are 1 to 10 ml.
- auxiliaries in these liquid formulations are: solvents (eg water, alcohol, natural and synthetic oils, eg medium-chain triglcerides), solubilizers (eg glycerol, glycol derivatives), wetting agents (eg polysorbate , Sodium lauryl sulfate), as well as other auxiliaries, which are needed for the preparation of pharmaceutical formulations of the desired properties, eg viscosity increasing agents, e.g. pH corrigents, e.g. Sweeteners and flavors, e.g. Antioxidants, e.g. Stabilizers, e.g. Preservative.
- solvents eg water, alcohol, natural and synthetic oils, eg medium-chain triglcerides
- solubilizers eg glycerol,
- Main constituents of the casings of capsule formulations are, for example, gelatin or hydroxypropylmethylcellulose. - -
- the oral route of administration is preferred.
- Another object of the present invention are pharmaceutical compositions containing the components A and B, usually together with one or more inert, non-toxic, pharmaceutically suitable excipients.
- components A and B according to the invention which contain the two components in crystalline (ground or micronized) and / or amorphous and / or dissolved form are suitable .
- Influence on absorption from the gastrointestinal tract may e.g. about the dissolution rate and thus the particle size of the components A and B are used.
- Suitable forms of application include (enteric) coated or uncoated tablets, gelatin hard capsules, HPMC, pullulan or other materials, soft gelatin capsules, powders, granules and pellets.
- controlled-release formulations are suitable. These include, for example, scaffold tablets, erosion matrix tablets, tablets or minitablets with diffusion-controlling coating, capsules with pellets, granules or tablets with diffusion-controlling coating, capsules with eroding pellets, granules or tablets and osmotically releasing tablets.
- scaffold tablets erosion matrix tablets, tablets or minitablets with diffusion-controlling coating
- capsules with pellets, granules or tablets with diffusion-controlling coating capsules with eroding pellets, granules or tablets and osmotically releasing tablets.
- the components A and B used according to the invention can be converted into the stated application forms. This can be done in a conventional manner by mixing with inert, non-toxic, pharmaceutically suitable excipients.
- the two components in the dosage form can be spatially separated.
- the two components or a powder, granules or a pellet preparation, the or at least one of the two Contains components to coat with polymer and subsequently processed into a tablet or capsule.
- component B Owing to the pH-dependent instability of component B, it is preferable to coat the formulation stage containing this component (eg active ingredient crystals, granules, pellets or minitablets, see later) or the entire formulation with an enteric coating. Coatings in the sense of this invention are in particular film coatings. The process of painting follows general standard procedures and requires the addition of other auxiliaries.
- softeners for example polyethylene glycols, triacetin, glycerol, dibutyl phthalate
- dyes / pigments eg titanium dioxide, iron oxide
- release agents eg, Talc, fumed silica, silica gel, magnesium stearate, glycerol monostearate.
- the coating is carried out by spraying a suspension, preferably on an aqueous basis. An exchange of the water by a suitable organic solvent is possible. A corresponding coating can be done at different points of the manufacturing process.
- a further coating for example in the form of a sugar or film coating, can also take place at the end of the production process.
- the preferred film formers at this point are, for example, modified celluloses, polymethacrylates and polyvinylpyrrolidone.
- a delayed, controlled release of components A and / or B may be particularly advantageous. This can lead to an improved pharmacological effect, reduce the occurrence of undesired side effects or contribute to a therapy simplification for the patient.
- the invention therefore also formulations which contain both components and deliver both components or one of the two components in a controlled manner. In this case, both component A and component B, only component A or component B can be delivered in a controlled manner, while in the latter two cases, the other portion is released quickly.
- the fixed combination according to the invention is inter alia a formulation which releases the components A and / or B quickly.
- fast-release formulation such a formulation (eg tablet, capsule, sachet) which releases> 80% of its containing active substance doses within 30 minutes (UV-detection device; release medium 900 ml 0, 1 N hydrochloric acid or acetate buffer pH 4.5 ⁇ surfactant, rotation speed 75 rpm) be applied to this invention up to three times a day; preferred is a combination that allows 1 to 2 times daily dosing.
- powders and / or granules and / or pellets which are subsequently filled into capsules or sachets, 1-coat / 2-coat or coat-core tablets, film-coated tablets, dragees or soft gelatin capsules can be distinguished.
- a dosage form containing the inventive fixed combination of components A and B carried out by filling a mixture of both components with the addition of suitable excipients directly into a capsule and / or formulated into a tablet.
- suitable excipients u.a. Fillers, disintegrants and lubricants into consideration.
- auxiliaries may be: fillers: cellulose derivatives (eg microcrystalline cellulose) and starches (native or modified, eg potato starch), sugars (eg lactose) and sugar alcohols (eg mannitol, sorbitol) and inorganic fillers (eg calcium phosphate, Magnesium oxide) and buffer substances; as disintegrants: starch derivatives (e.g., cross-linked sodium carboxymethyl starch, sodium starch glycolate), cellulose derivatives (e.g., cross-linked sodium carboxymethyl cellulose) or cross-linked polyvinyl pyrrolidone; as a lubricant (understood here as a generic term for flow regulator / lubricant / mold release agent): magnesium stearate, calcium stearate, stearic acid, talc and fumed silica.
- fillers cellulose derivatives (eg microcrystalline cellulose) and starches (native or modified, eg potato starch), sugars (
- the present invention also relates to a further processing of the previously described active ingredient ZHelps mixture to form a granulate.
- the known conventional processes in the form of fluidized-bed agglomeration, rotor granulation and moisture extrusion as wet granulation processes and roll compacting as dry granulation processes are suitable for granulation.
- the preferred wet granulation method is fluidized-bed agglomeration.
- solvent water or a suitable organic solvent for example ethanol, acetone or isopropanol, or a mixture of water with a suitable organic solvent.
- hydrophilizing agents in the form of surfactants (eg sodium lauryl sulfate, polysorbate) is possible.
- binders for example sugars, sugar alcohols, starches, cellulose derivatives, alginates, pectins, polyethylene glycols and polyvinylpyrrolidone.
- antistatic agents especially in finer areas of the drug, is possible.
- the granules produced can be filled directly (Sachet / capsule) or further formulated into tablets.
- the resulting dosage form ie capsule, tablet or even the granules (for sachet filling) can be provided with an enteric coating for reasons of stability.
- the production of the fixed combination can also be effected by the production of two mutually independent mixtures / granules which are combined in an additional process step and filled thereon (capsule / sachet) and / or formulated into a tablet.
- Each individual production step can be characterized by the addition of suitable auxiliaries.
- the preferred granulation process for both Component A and Component B is a dry granulation process. The processing to the final dosage form takes place after combination of both granules.
- the production of a rapid-release dosage form containing the inventive fixed combination of components A and B can also be done by drawing both components on neutral pellets.
- For the production of fast-release pellets with the abovementioned components A and / or B it is possible, for example, to coat neutral pellets of sucrose or microcrystalline cellulose with a mixture of the active compounds, customary binders and other customary auxiliaries. If a batch of pellets is produced per component, the pellet forms containing components A and B are subsequently combined to form a batch. These pellets can be filled into capsules and / or sachets or further processed into tablets.
- a press with two filling and pressing stations is particularly suitable for producing a 2-layer tablet.
- Each component is supplied as a direct mixture with suitable auxiliaries or in the form of granules at a respective filling station.
- the separate enteric coating of only one or both granules of components A and B or an enteric coating of the resulting 2-layer tablet, an enteric coating of the core only or an enteric coating of the resulting sheath-core tablet is possible ,
- the present invention also relates to the production of a fixed combination using melt extrusion, a process which also follows standard processes.
- component A may be e.g. in the form of one of the active ingredient / excipient mixtures or granules already described, while component B is first processed into a melt extrudate.
- the melt extrusion process requires the use of one or more polymers, plasticizers and carriers. Suitable polymers may be e.g. Hydroxypropyl cellulose or polyvinylpyrrolidone. As plasticizers come u.a. Triethycitrate, benzoic acid and succinic acid in question.
- excipients adjuvants such as e.g.
- the resulting melt extrudate is either rounded into pellets or comminuted after its production, preferably to a particle size ⁇ 0.315 [mm], and can be further processed subsequently with the powder / granule mixture containing component A.
- a direct filling as granules (sachet / capsule) or a compaction into tablets (1-layer or 2-layer tablets) take place. Addition of lubricants is recommended under these conditions.
- the preparation of the fixed combination can also be achieved by the production of two independent melt extrudates, which are combined in an additional process step and then filled and / or formulated into tablets (1-shift or 2-shift tablets).
- Each individual production step can be characterized by the addition of suitable auxiliaries.
- the pellets / granules thus obtained are mixed.
- the mixed extrusion pellets can be directly packed (sachet / capsule) or the mixed granules pressed into tablets.
- the production of a fixed combination is also the subject of this invention by the common melt extrusion of both active substances in an active ingredient / excipient mixture.
- a rounding off to pellets or a comminution of the melt extrudate, preferably to a particle size ⁇ 0.315 mm follows.
- the pellets thus obtained can be packed directly (Sachet / capsule) or the granules are compressed into tablets.
- the enteric coating there are various options for the enteric coating to be carried out: the resulting extrudates (granules or pellets) can be coated separately or after their mixing, or the resulting dosage forms (capsule / tablet) can be coated.
- the controlled release of active ingredient is likewise defined by the release rate of components A and / or B from the formulation.
- the pharmaceutical formulations of the present invention are tested in "Apparatus 2" of the USP (test medium 900 ml of phosphate buffer pH 6.8 ⁇ surfactant, rotation speed 75 rpm, UV detection) a controlled release of active ingredient, if for the delayed release / s a release rate of 80% in more than 45 minutes, preferably between 80% in 2 hours to 80% results in 16 hours.
- the components A and B in controlled release form, individual crystals of the active ingredients, active ingredient-containing granules or pellets can be provided with a coating and subsequently filled into capsules or pressed into tablets. Even tablets themselves can be wrapped.
- auxiliaries fats, waxes and various polymers are used.
- the coating of digestible or non-digestible fats or fat-like substances For example, glycerol monostearate, glycerol monopalmitate, stearic acid, diglycol stearate or glycerol trioleate can be used as digestible substances and, for example, carnauba wax, beeswax and cetystearyl alcohol as indigestible substances.
- Suitable pore formers for controlling the pore size include soluble polymers, such as, for example, polyethylene glycols, polyvinylpyrolidones, hydroxypropylmethylcelluloses, carboxymethylcelluloses or their salts, methylcelluloses, dextrins, maltodextrins, cyclodextrins, dextranes or other soluble compounds, for example salts (sodium chloride, potassium chloride, ammonium chloride etc.), urea, sugars (glucose, sucrose, fructose, lactose, etc.), sugar alcohols (mannitol, sorbitol, lactitol, etc.).
- soluble polymers such as, for example, polyethylene glycols, polyvinylpyrolidones, hydroxypropylmethylcelluloses, carboxymethylcelluloses or their salts, methylcelluloses, dextrins, maltodextrins, cyclodextrins, dextranes or other
- diffusion-controlling pellets are suitable for the formulation of the components A and B in controlled release form for subsequent filling into a capsule / sachet or for subsequent tableting.
- neutral pellets of sucrose or microcrystalline cellulose for example, are coated with a mixture of the active compound, customary binders and other customary auxiliaries and then coated with a diffusion varnish which may contain a plasticizer.
- the binders used are preferably hydroxypropyl methylcellulose or polyvinylpyrrolidone.
- methylcellulose hydroxypropylcellulose, sodium carboxymethylcellulose, polyacrylic acids, polyvinyl alcohols or gelatin
- Ethylcellulose is particularly suitable as diffusion coating.
- other materials such as poly [(methacrylic acid) (ethyl acrylate)] (1: 1) or other acrylates, cellulose acetate or cellulose acetate butyrate may also be used.
- Suitable plasticizers include phthalic acid derivatives (eg dimethyl phthalate, diethyl phthalate, dibutyl phthalate), citric acid derivatives (eg triethyl citrate, tributyl citrate, acetyl triethyl citrate), other esters (eg diethyl sebacate, triacetin), fatty acids and derivatives (glycerol monostearate, acetylated fatty acid glycerides, castor oil and other native oils , Miglyol), or polyols (glycerol, 1,2-propanediol, polyethylene glycol of different chain length).
- phthalic acid derivatives eg dimethyl phthalate, diethyl phthalate, dibutyl phthalate
- citric acid derivatives eg triethyl citrate, tributyl citrate, acetyl triethyl citrate
- other esters eg diethyl sebacate
- the type and amount of the plasticizer are adjusted so that the above-defined inventive release and the required stability of the pellets are achieved.
- the adjustment of the above-defined release is further effected by controlling the pore size of the diffusion coating and / or its thickness.
- the proportion of pore-forming agent in the paint amount is 0 to 50 wt .-%.
- Decisive for the production of pellets is the maintenance of a certain weight ratio of active ingredient-coated pellets to diffusion membrane as well as a certain ratio of diffusion varnish to amount of plasticizer. Parts of the plasticizer used can evaporate during painting and tempering. When changing the boundary conditions, a change in the coating amount of diffusion coating is required.
- the diffusion pellets can be prepared, inter alia, by suspending the components A and B in water and thickening them with a concentrated hydroxypropylmethylcellulose solution. The suspension or solution thus obtained is applied to neutral pellets in a fluidized-bed plant in a spraying process.
- pellets preferably in a fluidized-bed plant, by spraying, for example, an aqueous ethylcellulose dispersion or organic ethylcellulose solution which contains a suitable, physiologically compatible plasticizer.
- a diffusion membrane preferably in a fluidized-bed plant
- spraying for example, an aqueous ethylcellulose dispersion or organic ethylcellulose solution which contains a suitable, physiologically compatible plasticizer.
- the pellets are then tempered at temperatures of 50 to 125 ° C, preferably 60 to 110 0 C. In this case, higher temperatures of the heat treatment lead to the fact that, in order to achieve the release according to the invention, rather small amounts of lacquer application are sufficient and the resulting pellets are more physically stable during storage.
- the thickness of the diffusion membrane, type of plasticizer, amount of plasticizer and pellet size are chosen to achieve the above-described rate of release.
- the daily dose equivalent amount of pellets of both components is filled into a hard gelatin capsule or Sachet or further processed into tablets.
- other methods of pellet production are possible, such as the moisture extrusion with subsequent rounding, the rotor granulation, fluidized bed agglomeration or melt extrusion with subsequent rounding.
- minitablets with a diameter of 1 - 4 mm can be produced.
- the active ingredient-containing pellets or minitablets are coated with a diffusion membrane as described.
- enter an enteric coating If necessary, enter an enteric coating.
- Tablets comprising components A and B in a matrix of a water-swellable polymer are also suitable for formulating both components in fixed combination and controlled release form.
- the size of these tablets may be such that one or more tablets fit inside a capsule or sachet.
- the tablets may be filled in uncoated form into the capsule or previously coated with a varnish, for example a gastric juice-insoluble varnish.
- Tablets containing both components in a matrix of a water-swellable polymer can be prepared as follows. These so-called matrix formulations suitably contain 0.1 to 70 wt .-%, preferably 0.2 to 60 wt .-% of the active ingredients.
- the proportion of the matrix of the water-swellable polymer is expediently from 10 to 95% by weight, preferably from 20 to 60% by weight.
- Pharmaceutical preparations according to the invention in the form of erosion tablets are particularly preferred. These tablets are characterized in that in addition to customary auxiliaries and excipients as well as tabletting excipients they contain a certain amount of water-swellable, hydrogel-forming polymers, these polymers having a viscosity of at least 15, preferably at least 50 cps (measured as 2% aqueous solution at 20 0 C) must have.
- Typical excipients and carriers are, for example, lactose, microcrystalline cellulose, mannitol or calcium phosphates.
- Typical Tablettierosmittel are for example magnesium stearate, talc or fumed silica.
- magnesium stearate these are expediently present in an amount of from 0.5 to 3% by weight, in the case of highly disperse silicon dioxide, advantageously in an amount of from 0.1 to 1% by weight.
- Preferred water-soluble hydrogel-forming polymers are hydroxypropylcelluloses, hydroxypropylmethylcelluloses, methylcelluloses, carboxymethylcellulose, alginates, galactomannans, polyacrylic acids, polymethacrylic acids or copolymers of methacrylic acid and methyl methacrylate, guar, agar, pectin, tragacanth, gum arabic, xanthan or mixtures of these substances used. Particularly preferred is the use of hydroxypropyl methylcelluloses.
- the erosion tablets according to the invention should contain at least 10% by weight of a hydroxypropylmethylcellulose type, based on the mass of a tablet whose viscosity (measured as 2% strength aqueous solution at 20 ° C.) is at least 15, preferably at least 50 cps.
- the drug formulation comprising the active ingredient in a matrix of a water-swellable polymer is prepared by mixing the active ingredient, the polymer and suitable excipients and carriers, as well as conventional tableting excipients, and directly tableting.
- An advanced dry granulation in the form of roll compaction is just as possible as the performance of a wet granulation, in which the active ingredient, the water-swellable polymer and suitable carriers are granulated in the fluidized bed.
- the active ingredient, the water-swellable polymer and suitable carriers are granulated in the fluidized bed.
- the amount and viscosity of the water-swellable polymer are chosen to result in tablets having the above-described average release rates for both components.
- the dry granules are sieved, mixed with a lubricant, such as magnesium stearate, and tableted.
- the tablet is optionally subsequently varnished, if necessary with an enteric coating.
- the present invention also relates to a pharmaceutical formulation in which components A and B are present in a 2-layer tablet.
- This consists of either two controlled release layers or one controlled and one rapidly releasing layer.
- the formulation of each controlled release layer is based on the principles previously set forth for the matrix formulation.
- For tabletting is particularly suitable provided with 2 filling and pressing stations 2-layer press.
- the tablet is optionally subsequently varnished; if necessary, this coating can be done with an enteric coating.
- the two-layer tablet can also be provided with a third, drug-free layer.
- components A and B can also be processed into a 1-layer tablet.
- Suitable controlled-release formulations for subsequent incorporation into a 1-layer tablet are, in particular, the diffusion-controlling pellets already described. Either two types of diffusion-controlling pellets or one type of diffusion-controlling pellets are mixed with the active substance to be combined in rapid release form and further excipients, carriers and tableting auxiliaries and pressed into a 1-shift tablet. Granulation of the rapidly releasing active ingredient and subsequent coating of the tablet are also possible.
- enter an enteric coating If necessary, enter an enteric coating.
- osmotic drug delivery system Another embodiment of the present invention is the so-called osmotic drug delivery system.
- osmotic drug delivery systems are generally known in the art and are discussed in detail, for example, in RW Baker, Osmotic Drug Delivery: A Review of the Patent Literature, Journal of Controlled Release 1995, 35: 1-21 or in RK Verma et al., Osmotic Pumps in Drug Delivery, Critical Reviews in Therapeutic Drug Carrier Systems 2004, 21: 477-520.
- the drug formulation as an osmotic drug delivery system is preferably composed
- a core which contains the components A and B, optionally a hydrophilic polymeric swelling agent and optionally a water-soluble substance for inducing the osmosis, and
- hydrophilic polymeric swelling agents With regard to suitable hydrophilic polymeric swelling agents, reference is made to the polymeric swelling agents mentioned in EP 0 277 092 and WO 96/40080.
- ethylene oxide homopolymers polyethylene glycol
- vinylpyrrolidone vinyl acetate copolymers and other water-swellable polymers mentioned in US Pat. Nos. 3,865,108, 4,002,173 and 4,207,893 can be used.
- Water-soluble substances for inducing osmosis are, in principle, all water-soluble substances, the use of which is harmless in pharmacy, which is e.g.
- Components A and B of the present invention can be incorporated into an osmotic drug delivery system in a variety of ways. For the controlled release of both components they are mixed with the excipients and compressed to a common drug layer. If only one component is to be released in a controlled manner, the component not to be released in a controlled manner can either be introduced separately into the coating shell of the tablet, or it is pressed into a separate active ingredient layer which is first pumped out of the drug release system before the component to be released in a controlled manner.
- o-acetylsalicylic acid 80 mg o-acetylsalicylic acid and 20 mg omeprazole are used to prepare a tablet optionally with the addition of other adjuvants.
- o-acetylsalicylic acid 100 mg o-acetylsalicylic acid and 20 mg omeprazole are used to prepare a tablet optionally with the addition of other auxiliaries.
- o-acetylsalicylic acid 500 mg o-acetylsalicylic acid and 15 mg lansoprazole are used to prepare a tablet optionally with the addition of other adjuvants.
- o-acetylsalicylic acid 100 mg is used to prepare a tablet, optionally with the addition of further auxiliaries.
- o-acetylsalicylic acid 500 mg o-acetylsalicylic acid and 40 mg omeprazole are used to prepare a tablet optionally with the addition of other adjuvants.
- o-acetylsalicylic acid 500 mg o-acetylsalicylic acid and 20 mg omeprazole are used to prepare a tablet optionally with the addition of other adjuvants.
- 400.0 g of o-Acetylsalycylklare be charged with 150.0 g lansoprazole, 162.5 g of Avicel PH 101 ®, 100.0 g corn starch, 100.0 g sucrose, and 75.0 g AcDiSol ® homogeneously mixed and compacted.
- the resulting briquettes are sieved in 2 stages and mixed with 12.5 g of magnesium stearate.
- the final mixture is applied to a rotary press to 200.0 mg tablets weighing format WR 9 mm pressed 15 and this consisting in connection with an enteric coating of 28.0 g Eudragit L30D ®, 20.0 g talcum and 2.0 g triethylcitrate , dissolved or suspended in 200.0 g of water, provided.
- the 200 mg tablet core contains 80 mg o-acetylsalicylic acid and 30 mg lansoprazole.
- 640.0 g of o-acetylsalicylic acid are mixed homogeneously with 56.0 g of Avicel PH 101, 56.0 g of corn starch and 48.0 g of ascorbic acid and compacted.
- the resulting briquettes are sieved in 2 stages.
- the resulting briquettes are sieved in 2 stages.
- the granulate obtained is mixed with a mixture of 22.5 g Eudragit L30D ®, 20.0 g of talc and 2.5 g of glycerol monostearate dissolved or suspended in 180.0 g of water in a fluidized bed coated and enteric-coated with 2.0 g of Magnesium stearate mixed.
- 625.0 mg of the o-acetylsalicylic acid-containing and 165.0 mg of the omeprazole-containing granules are pressed on a 2-layer press into 790.0 mg tablets in the format 19 ⁇ 9 mm WR 5.7.
- These tablet cores contain 500 mg of o-acetylsalicylic acid and 40 mg of omeprazole. They are subsequently varnished with a mixture of 7.5 g of hydroxypropylmethylcellulose 15cp, 2.5 g of PEG 3350 and 2.5 g of titanium dioxide, dissolved or suspended in 154.2 g of water.
- pantoprazole 40.0 g of pantoprazole are homogeneously mixed with 40.0 g of mannitol and 440.0 g of HPC-SL and extruded. The resulting strand is cut into cylinders and these are rounded.
- Each 97.2 mg of roll granules containing o-acetylsalicylic acid are filled together with 130.0 mg pellets containing pantroprazole in capsules.
- Each Kpasel contains 81 mg o-acetylsalicylic acid and 10 mg pantroprazole.
- the capsules are with a mixture of 20.0 g Eudragit L30D ®, 19.5 g of talc and 2.0 g of triethyl citrate dissolved or suspended in 166.0 g of water, painted (enteric coating).
- 96Wall plates used: 96Wall plates, previously: cell culture-treated (351172 BD Biosciences), DMEM / F12 Powder Medium (42400-010 Invitrogen), or RPMI Powder Medium (51800-019 Vitrogen), Sea Plaque Agarose (50100 Cambrex) ( USA: Biowhittaker BMA 50100, 125grams), Cell Titer Blue (BestJ G8080, 20ml / G8081, 100ml / G8082, 10x100ml, Promega), cells: A549 (ATCC # CCL 185); HCT16 (ATCC # CCL 247).
- the cell suspension with Bottom Agar (44 ° C) 1 1 quickly and thoroughly in 50ml Falcon mixed. 50 ⁇ l of the mixture of top agar / cells are plated without touching the bottom agar and about 30 min. incubated at room temperature. Finally, 80 ⁇ l of DMEM / F12 (standard medium) is added as a final layer per well without touching the soft agar. The substance is added 24 hours after sowing. The substances are dissolved in DMSO in the concentrations given below and 10 .mu.l / well added. The incubation is carried out for 2 weeks in the presence of 1OmM Hepes buffer. The evaluation is carried out by means of the CTB assay according to the manufacturer's instructions (Promega), the calculation of the IC 50 using the program GraphPad Prism.
- Table 1 Activity of o-acetylsalicylic acid, lansoprazole or omeprazole or the respective combinations on tumor cells (HCT 116 colon carcinoma cells) in the Soft Agar Colony Formation Assay. (PPI: proton pump inhibitor - specification in the table column)
- Table 2 Activity of o-acetylsalicylic acid and lansoprazole or combinations on human lung carcinoma cells (A549) in the Soft Agar Colony Formation Assay.
- the growth of tumor cell colonies is markedly more inhibited by the combination of o-acetylsalicylic acid with the proton pump inhibitors lansoprazole or omeprazole than by o-acetylsalicylic acid alone.
- the miration assay is performed with DLD 1 cells (ATCC # CCL 221).
- the cells are grown in RPMI 1640 / Glutamine 1% / Glutamax 1% / (FCS 10%) and used at a confluence of approximately 80% for the assay.
- 750 ⁇ l of medium + 10% FCS, 1OnM IL-8 and 2OnM SDF-I are placed in each 24-well companion plate.
- the plate is heated to 37 ° C.
- the cells are then trypsinized from culture flasks, quenched with medium + 10% FCS, centrifuged, washed once with medium without FCS, resuspended and counted in a Neubauer chamber.
- 8 .mu.M single inserts (without fluoroblock) are set and charged with 500 .mu.l cells (equivalent to 5 ⁇ 10 5 cells / well). Substances are prepared in DMSO at the concentrations listed below and then added to the Companion Plate Medium (3.75 ⁇ l) and to the cells in the inserts (2.5 ⁇ l). After 48 hours migration time, the medium is removed from the inserts and washed in fresh Companion-plate with 500 .mu.l preheated D-PBS (Gibco).
- the inserts are placed in a new companion plate, each with 200 ul preheated Accutase and 10 minutes at 37 ° C without shaking and another 5 minutes incubated at 600 rpm in the Eppendorf Thermomixer.
- the inserts are then removed and from the companion-plate (bottom cells) are added in each case 150 .mu.l in white 96-well MTP and processed with CellTiter-Glo (Promega # G7571) according to the manufacturer's instructions.
- the measurement takes place in a Lumibox at 0.5% sensitivity.
- the evaluation is performed with Excel and GraphPad Prism.
- Table 3 Influence of a combination of o-acetylsalicylic acid and the proton pump inhibitor lansoprazole on the migration behavior of DLD-I colon carcinoma cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005047616A DE102005047616A1 (de) | 2005-10-05 | 2005-10-05 | Kombination |
PCT/EP2006/009199 WO2007039129A1 (de) | 2005-10-05 | 2006-09-22 | Kombination |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1933844A1 true EP1933844A1 (de) | 2008-06-25 |
Family
ID=37420994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06792208A Withdrawn EP1933844A1 (de) | 2005-10-05 | 2006-09-22 | Kombination |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1933844A1 (de) |
JP (1) | JP2009510139A (de) |
CA (1) | CA2624513A1 (de) |
DE (1) | DE102005047616A1 (de) |
WO (1) | WO2007039129A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2600147A1 (en) * | 2007-06-11 | 2008-12-11 | Nathan Bryson | Combination for treatment of diabetes mellitus |
MY186477A (en) | 2011-11-30 | 2021-07-22 | Takeda Pharmaceuticals Co | Dry coated tablet |
CN111514298B (zh) * | 2019-05-22 | 2022-04-08 | 苏州系统医学研究所 | 质子泵抑制剂与pd-1轴结合拮抗剂的组合及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7029701B2 (en) * | 2000-09-11 | 2006-04-18 | Andrx Pharmaceuticals, Llc | Composition for the treatment and prevention of ischemic events |
CA2554271A1 (en) * | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
-
2005
- 2005-10-05 DE DE102005047616A patent/DE102005047616A1/de not_active Withdrawn
-
2006
- 2006-09-22 JP JP2008533892A patent/JP2009510139A/ja not_active Withdrawn
- 2006-09-22 CA CA002624513A patent/CA2624513A1/en not_active Abandoned
- 2006-09-22 EP EP06792208A patent/EP1933844A1/de not_active Withdrawn
- 2006-09-22 WO PCT/EP2006/009199 patent/WO2007039129A1/de active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO2007039129A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2009510139A (ja) | 2009-03-12 |
DE102005047616A1 (de) | 2007-05-31 |
CA2624513A1 (en) | 2007-04-12 |
WO2007039129A1 (de) | 2007-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69628551T2 (de) | Oral anzuwendende pharmazeutische dosierungsformen,enthaltend einem protonenpunpeninibitor und einen nicht-steriodalen antiinflamatorischen wirkstoff | |
EP1830855B1 (de) | Feste, oral applizierbare pharmazeutische darreichungsformen enthaltend rivaroxaban mit modifizierter freisetzung | |
JP4088413B2 (ja) | 腸管を処置・治療するペレット製剤 | |
EP3556369B1 (de) | Orale pharmazeutische zusammensetzung mit verzögerter und kontrollierter freisetzung von olaparib und deren verwendungen | |
JP6976946B2 (ja) | 生理活性の強い、urat1のインヒビターを含む医薬組成物 | |
UA110853C2 (uk) | Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування | |
CA2909370A1 (en) | Sustained-release formulations of colchicine and methods of using same | |
KR20110081316A (ko) | 디아세레인 함유 약제학적 조성물 | |
AU2018341479A1 (en) | Niraparib formulations | |
EA031719B1 (ru) | Оральные составы деферазирокса | |
WO1998000114A2 (de) | Stabile arzneiform mit benzimidazolderivaten als wirkstoff zur oralen verabreichung und verfahren zu ihrer herstellung | |
EP1113787A1 (de) | Agitationsunabhängige pharmazeutische multiple-unit-retardzubereitungen und verfahren zu ihrer herstellung | |
DE202006020331U1 (de) | Neue, pharmazeutische modifizierte Freisetzungs-Dosisform Cyclooxygenase-Enzym-Inhibitor | |
US11717494B2 (en) | Oral solid cannabinoid oil composition for treating gastrointestinal disorders | |
WO2007039129A1 (de) | Kombination | |
DE19850445A1 (de) | Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen | |
EP2384745A2 (de) | Pharmazeutische Zusammensetzungen mit modifizierter Freisetzung aus Dexlansoprazol | |
AU2021345210A1 (en) | Multiparticulate dosage forms comprising deutetrabenazine | |
WO2011000518A1 (en) | Pharmaceutical composition comprising desloratadine | |
EP0324947B1 (de) | Synergistische Kombination von Decarboxylasehemmern und L-Dopa-Pellets | |
EP3305282A2 (de) | Zusammensetzung aus pranlukast-haltiger fester zubereitung mit verbesserter bioverfügbarkeit und verfahren zur herstellung davon | |
WO2019135725A1 (en) | Combinations of selective cox-2 inhibitor nsaids and h2 receptor antagonists for fast treatment of pain and inflammation | |
KR101016832B1 (ko) | 위장관 궤양의 치료를 위한 매스틱 함유 복합제제 | |
WO2019030610A1 (en) | PHARMACEUTICAL COMPOSITIONS WITH DUAL DIRECTLY COMPRESSIBLE MEDICAMENT RELEASE | |
WO2018087109A1 (de) | Multipartikuläre arzneiform mit kontrollierter freisetzung von metamizol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080506 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: WEBER, OLAF Inventor name: ZIEGELBAUER, KARL Inventor name: WAGNER, HEIKE Inventor name: STEINDL, LUDWIG |
|
17Q | First examination report despatched |
Effective date: 20081216 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090428 |